-
Detailed Analysis
Download Detailed Report Add to Watchlist
Values as of: 2021-01-25
Values as of: 2021-01-25
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through two segments, Product and Licensing. The company offers oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and cryoablation technology for use in kidney cancer. It also provides vascular products consisting of EKOS blood clot treatment devices; arterial blockage crossing devices; Varithena for the treatment of varicose veins; and sentry inferior vena cava filters. In addition, the company offers acute care products, such as CroFab, DigiFab, and Voraxaze. Further, it provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company was formerly known as British Technology Group International plc and changed its name to BTG plc in March 1995. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.
Employees : 1,724
Fiscal Year End : March
Currency: USD
Country : USA
Beta : 0.33
Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
---|---|---|---|---|---|
SSNLF | Samsung Electronics Co., Ltd |
N/A |
USD15,011.80B | 9.00 | N/A |
DISPF | Disco Corporation |
N/A |
USD3,369.71B | 18.60 | -488.90 |
BMYMP | Bristol-Myers Squibb Company P.. |
N/A |
USD1,841.23B | 4,990.00 | N/A |
CHKDJ | Chesapeake Energy Corporation .. |
N/A |
USD1,315.84B | N/A | N/A |
BAMKL | Bank of America Corporation |
N/A |
USD267.26B | 9.28 | N/A |
JGSMY | JG Summit Holdings, Inc |
N/A |
USD205.43B | 43.38 | 0.27 |
NCRRP | NCR Corporation 5.5% PFD CNV A |
N/A |
USD169.92B | 1,197.30 | N/A |
BPHLY | Bank of the Philippine Islands |
N/A |
USD160.15B | 15.34 | N/A |
UNLNF | Unilever N.V |
N/A |
USD158.01B | 24.49 | N/A |
LLOBF | Lloyds Banking Group plc 9.25%.. |
N/A |
USD134.80B | N/A | N/A |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|
N/A
Market Performance vs. Industry/Classification (Other) |
Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 12 Months | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 5 Years | |||||||
Capital Gain | 17.54% | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 17.54% | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 6.65% | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 6.65% | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 21.22% | N/A | N/A | N/A | N/A | ||
Risk Adjusted Return | 31.32% | N/A | N/A | N/A | N/A | ||
Market Capitalization | 3.96B | N/A | N/A | N/A | N/A |
Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
B+ | 97%-89% | B | 83%-86% | B- | 80%-82% |
C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
F | 0%-59% |
Ratio vs. Industry/Classification (Other) |
Ratio vs. Market |
||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
Market Value | |||||||
Price / Earning Ratio | 35.26 | N/A | N/A | N/A | N/A | ||
Price/Book Ratio | N/A | N/A | N/A | N/A | N/A | ||
Price / Cash Flow Ratio | 29.39 | N/A | N/A | N/A | N/A | ||
EV/EBITDA | N/A | N/A | N/A | N/A | N/A | ||
Management Effectiveness | |||||||
Return on Equity | N/A | N/A | N/A | N/A | N/A | ||
Return on Invested Capital | 14.03% | N/A | N/A | N/A | N/A | ||
Return on Assets | N/A | N/A | N/A | N/A | N/A | ||
Debt to Equity Ratio | N/A | N/A | N/A | N/A | N/A | ||
Technical Ratios | |||||||
Short Ratio | N/A | N/A | N/A | N/A | N/A | ||
Short Percent | N/A | N/A | N/A | N/A | N/A | ||
Beta | 0.33 | N/A | N/A | N/A | N/A |
Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
B+ | 97%-89% | B | 83%-86% | B- | 80%-82% |
C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
F | 0%-59% |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company had positive total cash flow in the most recent four quarters.
There is nothing we particularly dislike